Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.

ABSTRACT:

Unlabelled

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. In the last decades pirfenidone an anti-inflammatory and anti-fibrotic agent has shown benefit in inhibit collagen production and has also demonstrated benefit in decline progression in IPF in physiological outcomes as Forced vital capacity (FVC), in clinical outcomes such as progression free survival (PFS) and a benefit in mortality but no in clinically relevant outcomes as exacerbations or worsening of IPF.

Methods

We conducted a systematic review to evaluate the effectiveness of physiological and clinical outcomes of pirfenidone compared to placebo in IPF. We performed a search with no language restriction. Two researchers performed literature search, quality assessment, data extr

SUBMITTER: Aravena C 

PROVIDER: S-EPMC4550327 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature